<DOC>
	<DOCNO>NCT01186744</DOCNO>
	<brief_summary>The primary objective study 1 ) compare efficacy responses CP 690,550 ( 5 mg BID 10 mg BID ) versus placebo follow 24 week CP 690,550 treatment subsequent withdrawal active treatment various timepoints 16 week double blind active placebo treatment period ; 2 ) evaluate regain efficacy responses CP 690,550 ( 5 mg BID 10 mg BID ) follow 4 -16 week CP 690,550 treatment withdrawal subsequent treatment ; 3 ) evaluate safety tolerability CP 690,550 ( 5 mg BID 10 mg BID ) subject moderate severe chronic plaque psoriasis candidate systemic therapy phototherapy .</brief_summary>
	<brief_title>A Study To Evaluate The Effects And Safety Of Treatment , Treatment Withdrawal , Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>18 year old diagnosis plaquetype psoriasis ( psoriasis vulgaris ) least 12 month prior first dose study drug ; Psoriasis Area Severity Index ( PASI ) score 12 great , AND Physician 's Global Assessment ( PGA ) score 3 ( moderate ) 4 ( severe ) ; Psoriasis cover least 10 % body surface area ; No evidence active latent inadequately treated infection Tuberculosis serious infection . Nonplaque drug induce form psoriasis ; Can discontinue current oral , injectable topical therapy psoriasis discontinue phototherapy ( Psoralen Ultraviolet A ; Ultraviolet B ) . Any uncontrolled significant medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>OPT Retreatment</keyword>
	<keyword>OPT</keyword>
	<keyword>chronic</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>treatment withdrawal</keyword>
	<keyword>retreatment</keyword>
	<keyword>retreatment withdrawal</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>nail psoriasis</keyword>
	<keyword>Jak-inhibitor</keyword>
	<keyword>oral treatment</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Itch</keyword>
	<keyword>DLQI</keyword>
	<keyword>rebound</keyword>
	<keyword>intermittent</keyword>
	<keyword>retreat</keyword>
</DOC>